What is GHK-Cu?
GHK-Cu is a copper-binding tripeptide consisting of the sequence glycyl-L-histidyl-L-lysine (GHK) complexed with divalent copper, Cu(II). The GHK sequence was first isolated from human plasma in the 1970s and shown to bind copper with high affinity through coordination between the imidazole nitrogen of histidine, the α-amino nitrogen of glycine, and adjacent backbone atoms.
PX1 Research supplies lyophilized GHK-Cu as a reference compound for in-vitro dermatological, extracellular-matrix and wound-healing research. It is offered strictly for research use only — not for human or veterinary use.
Mechanism of action
GHK-Cu's biological activity in preclinical systems is inseparable from its copper coordination chemistry. The peptide serves as a copper carrier and delivery vehicle, and multiple reports have linked GHK-Cu exposure to changes in expression of extracellular-matrix genes, collagen and glycosaminoglycan synthesis in dermal fibroblast cultures, and modulation of antioxidant enzymes.
Gene-expression profiling studies in the published literature have reported broad transcriptional effects of GHK-Cu across hundreds of genes involved in tissue remodeling and repair, though the exact upstream receptor(s) remain an active area of investigation.
Research history
The GHK sequence was first identified by Loren Pickart in 1973 as a component of human plasma that stimulated hepatic growth in cell culture. Subsequent decades established its copper-binding stoichiometry, characterized structural analogs, and extended the research to skin, hair-follicle and wound-healing models.
GHK-Cu remains one of the most cited copper peptides in the biochemical literature.
Laboratory handling and storage
GHK-Cu ships as a lyophilized blue-tinted powder — the color arises from the Cu(II) chromophore. Store between −20°C and −80°C protected from light. Warm to room temperature before opening.
Reconstitute aseptically with bacteriostatic or sterile water for research reconstitution added down the vial wall and swirl to dissolve. Avoid strong chelators or acidic solutions during reconstitution as they can disrupt copper coordination. Store the reconstituted solution at 2–8°C protected from light and aliquot to minimize freeze-thaw cycles.
Purity and Certificate of Analysis (COA)
Every PX1 GHK-Cu batch is USA-manufactured and released at ≥99% purity by reversed-phase HPLC. Identity of the GHK tripeptide is confirmed by LC-MS against the theoretical monoisotopic mass, and copper content is verified against the specified copper-to-peptide stoichiometry. The batch-specific COA is published on this product page.
Testing methods
Each GHK-Cu lot is released against reversed-phase HPLC purity, LC-MS identity, copper stoichiometry verification, kinetic chromogenic LAL endotoxin, residual solvents by GC, water content by Karl Fischer titration and appearance/reconstitution visual inspection.
Copper coordination chemistry and why it defines the molecule
GHK-Cu cannot be understood as a peptide with a metal impurity; the copper is part of the active species. The glycyl-L-histidyl-L-lysine backbone coordinates Cu(II) through the imidazole nitrogen of the histidine side chain, the N-terminal α-amino nitrogen and the deprotonated backbone amide nitrogen, forming a square-planar complex with high affinity. The binding constant is high enough that GHK competes effectively for copper in physiological environments, which is the basis for describing it as a copper carrier rather than merely a copper salt.
This chemistry has practical laboratory consequences. Strong chelators, EDTA-containing buffers and low-pH solutions can strip or destabilize the complex, converting the material back toward free GHK plus dissociated copper — an entirely different test article. Reconstitution medium should therefore be chosen deliberately, and the characteristic blue color of the solution is a first-order visual indicator that the complex is intact.
The copper also creates an analytical requirement absent from ordinary peptides: stoichiometry. A release specification for GHK-Cu must confirm not only the purity and identity of the tripeptide but the copper-to-peptide ratio, typically by an elemental method. Material sold as GHK-Cu that is characterized only by HPLC purity of the tripeptide has not actually been characterized as GHK-Cu.
Analytical characterization
Laboratories that work with GHK-Cu typically characterize incoming material on three axes before it enters a study: identity, purity and content. Identity is established by high-resolution mass spectrometry against the theoretical monoisotopic mass (340.8 Da for the tripeptide-copper complex; 340.4 Da for free GHK), usually supported by MS/MS fragmentation that walks the backbone and confirms the sequence rather than just the total mass. A matching intact mass alone can be satisfied by a scrambled or partially epimerized sequence, which is why fragmentation data is the stronger identity evidence.
Purity is quantified by reversed-phase HPLC with UV detection, integrating every resolved peak in the chromatogram and expressing the main peak as a percentage of total area. The gradient matters more than the headline number: a shallow, well-optimized gradient resolves closely eluting process impurities such as deamidation products, oxidation variants, truncated sequences and acetate adducts, while an aggressive gradient can co-elute them under the main peak and inflate the reported purity. PX1 publishes the chromatogram itself, not only the integrated figure, so the resolution behind the number is auditable.
Content — how much peptide is actually in the vial once counter-ions and residual water are subtracted — is the axis most often skipped by low-cost suppliers. Net peptide content is a function of the labeled mass, the water content measured by Karl Fischer titration, and the counter-ion (typically trifluoroacetate or acetate) load. A vial that is 99% pure by HPLC can still under-deliver on content if it carries a high salt and moisture fraction, which is why the COA reports both.
Solubility, reconstitution and stability behavior
GHK-Cu is supplied as a lyophilized blue-tinted powder, the color arising from the Cu(II) chromophore. The lyophilized cake is the most stable form of the molecule and should be kept sealed at −20°C or below, protected from light, until the study begins. The single most common handling error in a research setting is opening a cold vial: atmospheric moisture condenses onto the cake the moment the stopper is broken, and that water starts hydrolytic degradation before reconstitution has even happened. Always equilibrate the sealed vial to room temperature first.
Reconstitution should be performed aseptically with bacteriostatic or sterile water for research reconstitution, introduced slowly down the inner wall of the vial rather than streamed directly onto the cake. Swirl — never shake. Peptides are surface-active, and vigorous agitation drives them to the air-liquid interface where they unfold and aggregate; visible foaming is a sign that material has already been lost to interfacial denaturation. Full dissolution to a clear, particle-free solution normally takes under a minute of gentle swirling.
Once in solution the molecule is far more labile than it was as a powder. Reconstituted GHK-Cu should be held at 2–8°C, protected from light, and aliquoted immediately into single-use volumes so that the working stock is never subjected to repeated freeze-thaw cycling. Each freeze-thaw cycle contributes measurable loss through aggregation and adsorption to container surfaces. Low-binding polypropylene tubes reduce adsorptive loss at dilute concentrations, and a carrier protein is commonly added to very dilute working solutions for the same reason.
Documented research applications
The GHK-Cu literature is one of the longest-running in the peptide field, beginning with Pickart's 1973 identification of the sequence in human plasma. Dermatological and extracellular-matrix research forms the largest cluster: collagen and glycosaminoglycan synthesis in fibroblast culture, matrix metalloproteinase and tissue inhibitor expression, and remodeling behavior in wound-healing models.
A second cluster uses gene-expression profiling. Broad transcriptional surveys have reported that GHK-Cu exposure shifts expression across a large number of genes associated with tissue remodeling, DNA repair and antioxidant response, and these datasets are frequently reused in bioinformatics work rather than generated fresh.
A third area is hair-follicle and appendage biology, and a fourth examines the peptide's antioxidant and metal-handling behavior directly as coordination chemistry. Because the compound is studied both as a biological signal and as a copper delivery vehicle, laboratories generally specify both the peptide purity and the copper stoichiometry in their methods sections — a level of characterization the batch COA on this page is designed to supply.
Sourcing, provenance and what separates lab-grade material
The research-peptide market is unusually wide in quality. The same nominal GHK-Cu listing can represent USA-manufactured material released against a documented specification, or repackaged bulk of unknown origin with a generic certificate that was never generated from the lot in the vial. The distinction is invisible from the product photo and only becomes visible in the paperwork.
The practical test is traceability: the lot number printed on the vial label should appear on the certificate of analysis, and that certificate should show the actual chromatogram and mass spectrum for that lot rather than a representative example. A COA without a lot number, without instrument traces, or dated years before the vial was filled is a document, not evidence. PX1 publishes the batch-specific report directly on the product page so the chain from manufacturing to vial is checkable before purchase.
Beyond the certificate, consistent lab-grade supply depends on synthesis and release happening under one controlled process: domestic solid-phase manufacturing, preparative HPLC purification, lyophilization under validated cycle parameters, and third-party confirmation of purity and endotoxin. GHK-Cu sold by PX1 Research is produced and released on that pathway and is supplied strictly for laboratory research use — not for human or veterinary use.
Study design considerations
The first design decision in any GHK-Cu study is the copper control. Because the complex delivers copper, an effect observed with GHK-Cu may reflect the peptide, the copper or the combination. A rigorous design therefore includes three arms — GHK-Cu, free GHK at matched molar concentration, and a copper salt at matched copper concentration — and reports all three. Studies omitting the copper-only arm cannot attribute their result to the peptide.
Buffer chemistry is the second. Chelator-containing media, low pH and competing divalent cations can destabilize the complex during the experiment itself, meaning the test article at hour twenty-four may not be the test article at hour zero. Where the exposure window is long, verifying complex integrity at the end of the window — by absorbance or by an elemental method on the spent medium — converts an assumption into data.
Fibroblast culture is the workhorse system, with collagen and glycosaminoglycan synthesis, matrix metalloproteinase and TIMP expression as the standard readouts. Because these endpoints are sensitive to serum concentration and passage number, both should be fixed across arms and reported; drift in either is a frequent source of irreproducibility in the dermal literature independent of the compound.
For gene-expression work, the large public datasets generated on GHK-Cu make a re-analysis design viable without new bench work, and they also provide a strong prior against which new experiments can be compared. Designing a transcript panel around the pathways those datasets highlighted — remodeling, DNA repair, antioxidant response — is more informative than an unfocused whole-transcriptome run at low replication.
Blend designs follow the same decomposition rule as elsewhere: GLOW and KLOW preparations should be tested against their single components at matched concentrations, and for any copper-containing blend the copper stoichiometry of the finished preparation must be known, since combining a copper complex with additional peptides can alter the effective copper distribution.
Common research questions about GHK-Cu
Is GHK the same as GHK-Cu? No. GHK is the free glycyl-L-histidyl-L-lysine tripeptide; GHK-Cu is the copper(II) complex of that tripeptide. Nearly all of the biological literature concerns the copper complex, and the copper is part of the active species rather than an additive. Material sold as GHK-Cu but characterized only for tripeptide purity has not been characterized as the complex at all.
How can a laboratory tell the complex is intact? Color is the first-order indicator — the Cu(II) chromophore gives solutions a distinct blue tint, and a colorless solution labeled GHK-Cu warrants investigation. The definitive check is copper-to-peptide stoichiometry by an elemental method reported on the certificate, alongside the tripeptide purity by HPLC.
What can strip the copper? Strong chelators such as EDTA, low pH, and competing metal ions can destabilize or displace the complex. Reconstitution medium and any downstream buffer should therefore be chosen deliberately; a chelator-containing buffer converts the test article into free GHK plus dissociated copper, which is a different experiment than the one intended.
Why does GHK-Cu appear in gene-expression research so often? Broad transcriptional surveys reported that exposure shifts expression across a large number of genes linked to tissue remodeling, DNA repair and antioxidant response. Those public datasets are widely reused in bioinformatics work, which compounds the citation footprint and keeps the compound central to extracellular-matrix research decades after its 1973 identification in human plasma.
Why is GHK-Cu blended with BPC-157 and TB-500? The three address different axes of a repair model — extracellular matrix and copper handling, angiogenic signaling, and actin-driven cell migration respectively. Blended preparations such as GLOW and KLOW exist for that reason. Blends carry a heavier analytical burden: the release method must resolve every component in one run and, for any copper-containing blend, also confirm stoichiometry.
Where GHK-Cu sits in the PX1 catalog
GHK-Cu is stocked as a single peptide and as a component of the GLOW and KLOW blends, which pair it with BPC-157, TB-500 and, in KLOW, KPV. The blends exist because the copper-peptide extracellular-matrix axis is complementary to angiogenic and actin-driven repair rather than redundant with them.
For dermal and appendage research the relevant catalog neighbors are the copper-peptide preparations and the topical-oriented formats; for wound-model work the pairing with BPC-157 and TB-500 is the standard configuration. Where the copper chemistry itself is the object of study rather than the peptide biology, GHK-Cu is usually the only compound in the panel.
Every GHK-Cu lot is released with both tripeptide purity and copper stoichiometry documented, which is the specification that distinguishes a characterized copper complex from a peptide that merely contains copper. The batch report is published on the product page with a lot number matching the vial label.
References
- Pickart 1973. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. 1973;243(124):85-87.
- Pickart 2018. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987.
- Hostynek 2011. Hostynek JJ, et al. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflammation Research. 2011;60(1):79-86.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.